Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study.

Souichi Suenobu,Keita Terashima,Masaharu Akiyama, Tomoyo Oguri, Asako Watanabe,Masatoshi Sugeno,Mitsuo Higashimori,Karen So,Yoshihiro Nishida

Neuro-oncology advances（2023）

引用 0|浏览7

暂无评分

摘要

Consistent with results of the phase II SPRINT trial, 25 mg/m selumetinib twice daily was well tolerated with a manageable safety profile in Japanese children with NF1 and symptomatic, inoperable PN.

查看译文

关键词

neurofibromatosis type,inoperable plexiform neurofibromas,japanese pediatric patients,pediatric patients,open-label

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要